ASX Health Stocks: Nyrada gets closer to European patent, and HOPE for Zelira’s autism tincture
Health & Biotech
Health & Biotech
Link copied to
Cardiovascular and neurological diseases fighter, Nyrada (ASX: NYR), says the European Patent Office (EPO) has issued its intention to grant the company’s patent application number for its PCSK9 inhibitor technology.
The patent is expected to be granted by the EPO once the final administrative steps have been completed, which will then protect Nyrada’s PCSK9 inhibitor technology until 2038.
The patent builds on a corresponding patent granted by the US Patent and Trademark Office (USPTO) in July 2021. Notably, these patents are entirely owned by Nyrada, and the company’s IP assignment is free of royalties or other incumbrances.
PCSK9 is a naturally produced protein that plays a counter role in the body’s regulation of LDL cholesterol that restricts it from entering the bloodstream.
The protein does this by degrading the LDL receptors (LDLR) on the surface of liver cells, leading to increased levels of LDL cholesterol in the bloodstream which could potentially result in a heart attack or stroke.
Inhibition of PCSK9 causes a beneficial increase in LDLR on the surface of cells, improving the body’s ability to clear LDL cholesterol from the bloodstream.
“As we get closer to clinical testing of our PCSK9 inhibitor technology in healthy volunteers, it is prudent to have our IP protection in place to support our business development position,” said Nyrada CEO, James Bonnar.
“I am delighted that Nyrada’s PCSK9 inhibitor technology will soon be protected in two substantial markets, the US and Europe,” he added.
Zelira Therapeutics (ASX:ZLD) has published a white paper detailing the analysis of longitudinal, real-world data (RWD) generated from patients using HOPE.
HOPE is Zelira’s 100% organic tincture for people with autism spectrum disorder.
Results have shown that almost 70% of patients in the study cohort were rated by clinicians as having achieved at least ‘moderate’ therapeutic effect after five months on HOPE.
A total of 25 adverse events occurred in nine individuals, but no serious adverse events were observed. All adverse events were mild and transient.
The HOPE formulation was launched in Australia in October 2020, and is now available to prescribers and patients through the Therapeutic Goods Administrations (TGA) Special Access and Authorised Prescriber Schemes.
“Physicians and patients often ask for proof of the safety, efficacy, and dosing guidelines for cannabinoid-based medicines,” said Zelira Therapeutics CEO, Dr Oludare Odumosu.
“These results now provide additional clinical and regulatory validation for our products as we expand into highly regulated global markets,” he said.
AI-based medtech firm Beamtree Holdings (ASX:BMT) released a trading update this morning.
The company said that new contract wins since the start of 2022 were worth $16m in total contract value, and around $3m per annum in revenue over the next 12 months.
Beamtree has also accelerated international growth with sales of products and capabilities in the period, with its services now operating in more than 20 countries.
The company provides automation technology and data analytics that support health care providers to improve safety, increase effectiveness, and reduce the administrative burden on clinical staff.